Richard Barbano, MD
Neurology · Rochester, NYNPI 1114953924
Payments from drug & device makers
Across 38 payments — averaging $627.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$20K
- Acorda Therapeutics, Inc$3K
- Ipsen Biopharmaceuticals, Inc$555
- Merz North America, Inc.$114
- Amarin Pharma, Inc.$38
- Merz Pharmaceuticals, LLC$36
- plus $7 from 1 others
Across 14 payments — averaging $4042.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$35K
- Acadia Pharmaceuticals Inc$22K
What the payments were for
- Consulting fees$21,15589%
- Travel & lodging$1,9948%
- Food & beverage$5852%
- Education$1140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 30 | $20,273 |
| Acorda Therapeutics, Inc | 1 | $2,825 |
| Ipsen Biopharmaceuticals, Inc | 1 | $555 |
| Merz North America, Inc. | 1 | $114 |
| Amarin Pharma, Inc. | 2 | $38 |
| Merz Pharmaceuticals, LLC | 2 | $36 |
| GE HealthCare | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,848 in reported general payments places this provider in the 75th percentile of 1,623 neurology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Carbidopa-LevodopaCarbidopa/Levodopa | 56 | $2,929 |
| Baclofen | 34 | $1,082 |
| AmantadineAmantadine Hcl | 15 | $981 |
| Propranolol Hcl ErPropranolol Hcl | 12 | $942 |
| Clonazepam | 84 | $720 |
| Gabapentin | 29 | $418 |
| Propranolol Hcl | 21 | $317 |
| Cyclobenzaprine Hcl | 21 | $245 |
| Trihexyphenidyl Hcl | 11 | $100 |
| Paroxetine Hcl | 13 | $95 |
Paid to pharmacies, not to this prescriber.
Other neurology in Rochester
- Kathleen MungerRochester$1.1M
- Christian GrommesNew York$9.9M
- Ilya KisterNew York$9.5M
- E DorseyNew York$8.5M
- Lauren SchaffNew York$8.2M
- Richard HolubAlbany$6.3M
- Martin SadowskiNew York$5.4M
- Lawrence HonigNew York$4.9M
- Laszlo MechtlerAmherst$4.3M
- Bennett MyersAmherst$3.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.